For Research Use Only

Apolipoprotein Al Monoclonal antibody Catalog Number:66206-1-lg 12 Publications




Basic Information	Catalog Number: 66206-1-lg	GenBank Accession BC005380	Number:	Purification Method: Protein A purification
	Size:	GenelD (NCBI):		CloneNo.:
	150ul , Concentration: 1451 ug/ml by			1C9G5
	Nanodrop and 1067 ug/ml by Bradford method using BSA as the standard;	UNIPROT ID: P02647		Recommended Dilutions: WB 1:1000-1:4000
	Source:	Full Name:		IHC 1:50-1:500
	Mouse	apolipoprotein A-I		IF/ICC 1:50-1:500
	lsotype: IgG2b	Calculated MW: 31 kDa		
	Immunogen Catalog Number: AG21920	Observed MW: 26-28 kDa		
Applications	Tested Applications:		Positive Con	rols:
	WB, IHC, IF/ICC, FC (Intra), ELISA		WB : human p	lasma tissue,
	Cited Applications: WB, IHC		IHC : human	iver cancer tissue, mouse kidney tissue
	Species Specificity: IF/ICC : HepG2 cells,			52 cells,
	human, mouse			
	Cited Species: human, mouse, rat			
	Note-IHC: suggested antigen ra TE buffer pH 9.0; (*) Alternativ retrieval may be performed w buffer pH 6.0	vely, antigen		
	ApoA1 is a major protein component of high density lipoproteins (HDL) which is associated with reversed cholesterol transport, lipid/cholesterol binding, lecithin/cholesterol acyltransferase (LCAT) activation and specific receptors binding. It is synthesized in the liver and small intestine. Defects of ApoA1 cause low HDL level and systemic non-neuropathic amyloidosis. Serum concentration of ApoA1 is inversely related to the risk of developing atherosclerosis. This antibody was generated against the C-terminal region of human ApoA1.			
Background Information	cholesterol transport, lipid/cholestero receptors binding. It is synthesized in systemic non-neuropathic amyloidos	bl binding, lecithin/cl the liver and small i is. Serum concentrati	ntestine. Defects on of ApoA1 is in	ansferase (LCAT) activation and specific of ApoA1 cause low HDL level and aversely related to the risk of developing
	cholesterol transport, lipid/cholestero receptors binding. It is synthesized in systemic non-neuropathic amyloidos atherosclerosis. This antibody was ge	ol binding, lecithin/cl the liver and small i is. Serum concentrati nerated against the (ntestine. Defects on of ApoA1 is in	ansferase (LCAT) activation and specific of ApoA1 cause low HDL level and aversely related to the risk of developing
	cholesterol transport, lipid/cholestero receptors binding. It is synthesized in systemic non-neuropathic amyloidos atherosclerosis. This antibody was ge	ol binding, lecithin/cl the liver and small i is. Serum concentrati nerated against the (ntestine. Defects on of ApoA1 is in C-terminal regio	ansferase (LCAT) activation and specific of ApoA1 cause low HDL level and nversely related to the risk of developing n of human ApoA1.
Background Information Notable Publications	cholesterol transport, lipid/cholestero receptors binding. It is synthesized in systemic non-neuropathic amyloidos atherosclerosis. This antibody was ge Author Put Hideaki Morishita 31	ol binding, lecithin/cl the liver and small i is. Serum concentrati nerated against the C omed ID Jou 526472 Elif	ntestine. Defects on of ApoA1 is in C-terminal regio	ansferase (LCAT) activation and specific of ApoA1 cause low HDL level and oversely related to the risk of developing n of human ApoA1. Application
	cholesterol transport, lipid/cholestero receptors binding. It is synthesized in systemic non-neuropathic amyloidos atherosclerosis. This antibody was ge Author Put Hideaki Morishita 311 Ying Zhang 36:	ol binding, lecithin/cl the liver and small i is. Serum concentrati nerated against the (omed ID Jou 526472 Elif 172518 Fro	ntestine. Defects on of ApoA1 is in C-terminal regio rnal	ansferase (LCAT) activation and specific of ApoA1 cause low HDL level and oversely related to the risk of developing n of human ApoA1. Application WB
	cholesterol transport, lipid/cholestero receptors binding. It is synthesized in systemic non-neuropathic amyloidos atherosclerosis. This antibody was ge Author Put Hideaki Morishita 311 Ying Zhang 360 Zhonghao Li 364 Storage: Store at -20°C. Stable for one year after Storage Buffer: PBS with 0.02% sodium azide and 500	ol binding, lecithin/ci the liver and small i is. Serum concentrati nerated against the G omed ID Jou 526472 Elif 172518 Fro 498935 Int er shipment. % glycerol, pH7.3	ntestine. Defects on of ApoA1 is in C-terminal regio rnal e nt Nutr	ansferase (LCAT) activation and specific of ApoA1 cause low HDL level and oversely related to the risk of developin of human ApoA1. Application WB WB
Notable Publications	cholesterol transport, lipid/cholestero receptors binding. It is synthesized in systemic non-neuropathic amyloidos atherosclerosis. This antibody was ge Author Put Hideaki Morishita 311 Ying Zhang 361 Zhonghao Li 364 Storage: Store at -20°C. Stable for one year after Storage Buffer:	ol binding, lecithin/ci the liver and small i is. Serum concentrati nerated against the G omed ID Jou 526472 Elif 172518 Fro 498935 Int er shipment. % glycerol, pH7.3	ntestine. Defects on of ApoA1 is in C-terminal regio rnal e nt Nutr	ansferase (LCAT) activation and specific of ApoA1 cause low HDL level and oversely related to the risk of developin of human ApoA1. Application WB WB

For technical support and original validation data for this product please contact: T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free E: proteintech@ptglab.com in USA), or 1(312) 455-8498 (outside USA) W: ptglab.com


This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

Selected Validation Data


temperature for 1.5 hours.




human plasma were subjected to SDS PAGE followed by western blot with 66206-1-1g (APOA1 Antibody) at dilution of 1:2000 incubated at room




Immunohistochemical analysis of paraffinembedded human liver cancer tissue slide using 66206-1-1g (APOA1 Antibody) at dilution of 1:400 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunohistochemical analysis of paraffinembedded human liver cancer tissue slide using 66206-1-Ig (APOA1 Antibody) at dilution of 1:400 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).



Immunofluorescent analysis of (-20°C Ethanol) fixed HepG2 cells using 66206-1-Ig (APOA1 antibody) at dilution of 1:100 and Alexa Fluor 488conjugated AffiniPure Goat Anti-Mouse IgG(H+L).



1X10^6 HepG2 cells were intracellularly stained with 0.4 ug Anti-Human Apolipoprotein Al (66206-1-lg, Clone:1C9G5) and Coralite@488-Conjugated AffiniPure Goat Anti-Mouse lgG(H+L) at dilution 1:1000 (red), or 0.4 ug Control Antibody. Cells were fixed with 4% PFA and permeabilized with Flow Cytometry Perm Buffer (PF00011-C).